GLPwatch
Exenatide extended-release: a once-weekly option for patients with type 2 diabetes.
JAAPA · 2014
Last updated 2026-05-28Exenatide extended-release is a once-weekly injectable medication for type 2 diabetes that may help patients who struggle with weight loss, low blood sugar, or controlling their blood sugar with other treatments. It belongs to a class of drugs called GLP-1 agonists, which work by mimicking a natural hormone to improve blood sugar control.
AI summary of the abstract below.
| Journal | JAAPA, 2014 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.08 |
| NIH percentile | 6 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
Exenatide extended-release is a new long-acting glucagon-like peptide-1 agonist that may be an attractive option for patients desiring to lose weight, who are prone to hypoglycemic episodes, and who have not achieved desired glycemic control with current therapy.
Verbatim abstract via PubMed 24853156 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.